Drug Channels

MARCH 15, 2022

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Pharmacies and Pharmacy Benefit Managers , our 13th edition, provides a comprehensive, fact-based, and non-partisan tool for understanding the entire U.S. I am pleased to announce our new 2022 Economic Report on U.S.

Pharmacy 98

Pharmacy Specialty Pharmacies Licensing Licensing 98

Drug Channels

SEPTEMBER 21, 2022

The battle for control of the specialty patient continues. In 2022, specialty pharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs. However, buy-and-bill appears to have rebounded substantially at hospitals.

Specialty Pharmacies 97

Specialty Pharmacies Hospitals Pharmacy Pharmaceuticals 97

Drug Channels

APRIL 8, 2022

Michael discusses patient support challenges that are unique to specialty-lite pharmaceuticals. He goes on to describe four new categories of patient solutions and pharmacy models specific to this growing market segment.

Specialty Pharmacies 96

Specialty Pharmacies Pharmacy Production Pharmaceuticals 96

Drug Channels

DECEMBER 13, 2023

For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. This week, I’m rerunning some popular posts while I prepare for Fiday's Drug Channels Outlook 2024 live video webinar. d/b/a Drug Channels Institute.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Pharmaceuticals Production 98

Drug Channels

SEPTEMBER 13, 2023

For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. Time for our annual update on the channels for provider-administered drugs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Specialty Pharmacies 97

Specialty Pharmacies Pharmacy Pharmaceuticals Production 97

Drug Channels

OCTOBER 10, 2023

I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. we analyze the IRA’s likely consequences for wholesalers and the overall pharmaceutical business. and Section 6.4.3.

Pharmaceuticals 40

Pharmaceuticals Specialty Pharmacies Pharmacy Biosimilars 40

Drug Channels

SEPTEMBER 21, 2020

This important event convenes key stakeholders including manufacturers, specialty pharmacies, hubs, payers, PBMs, physicians and more to explore strategies for developing and integrating hub programs and other patient-centric services to ensure product access and optimal reimbursement. Arquette, R.Ph., REGISTER TODAY.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Production 52

Drug Channels

JULY 20, 2021

The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others. As you will see below, mail and specialty pharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Marketing Pharmaceuticals 52

Drug Channels

OCTOBER 19, 2020

Channel Strategy for First Medical Product – A Look at Channel Considerations for Pharmacy vs. Medical Plus – Tailored Track Options Based on Company Size : Emerging/Small Companies – Infrastructure Set-Up, License Procurement and 3PL Contracting Mid-Large Companies – How Do I Think About My Portfolio Differently Based on Product Type?

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Licensing 52

Drug Channels

NOVEMBER 8, 2020

Stuart Parker, Senior Director, Trade Relations, Mayne Pharma And more!

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Pharmaceuticals 52

Drug Discovery World

FEBRUARY 22, 2023

Craig Caceci, Managing Director at Terebellum, offers guidance to pharmaceutical companies that are in the position to take their drugs to market. With over 25 years’ experience in the pharmaceuticals sector, Craig drives the growth and operations of global specialty pharmacy and healthcare services provider, Terebellum.

Specialty Pharmacies 130

Specialty Pharmacies Drugs Marketing Clinical Trials 130

Drug Channels

JANUARY 4, 2021

Dave MacLeod, Head of Patient Services and Specialty Pharmacy Operations , Amylyx Pharmaceuticals Deepti Jaggi, Global Head of Patient Insights and Solutions , Astellas US Marina Allen, Executive Director, Patient Access and Reimbursement , Coherus BioSciences And more!

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Production 52

Drug Channels

APRIL 19, 2021

Up your compliance game at this important event serving the unique sector of Specialty Products, the 7th annual Virtual Compliance Congress for Specialty Products.

Compliance 40

Compliance Production Specialty Pharmacies Pharmacy 40

Drug Channels

APRIL 11, 2021

Koob, Assistant U.S. Attorney , U.S. Attorney’s Office for the Eastern District of Pennsylvania Jolie Apicella, Assistant U.S. Attorney, Chief, Health Care Fraud , U.S.

Specialty Pharmacies 40

Specialty Pharmacies Compliance Pharmacy Pharmaceuticals 40

The Pharma Data

JANUARY 12, 2021

Akin to the NASA Deep Space Network, SYNERGY-AI OCTCC is a real time data and communication network between patients, sites, and pharmaceutical companies, with the Massive Bio AI-enabled engine orchestrating these stakeholders for successful operations. NEW YORK–( BUSINESS WIRE )– Massive Bio, Inc. , 75N91020C00016.

Clinical Trials 52

Clinical Trials Trials Clinical Research Pharmaceutical Companies 52

The Pharma Data

OCTOBER 27, 2020

We commenced launch activities for the Remunity Pump for Remodulin, including shipping training devices to specialty pharmacies and certain health care practitioners, and entering into agreements with specialty pharmacies to purchase Remunity Pumps and accessories and to pre-fill the Remunity cartridges exclusively with Remodulin.

FDA 40

FDA Production Licensing Licensing 40

The Pharma Data

APRIL 4, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA ® (apalutamide) in the United States. Both tablet strengths are available via prescription through existing specialty pharmacy networks. FDA approval for mCSPC in September 2019.To

Specialty Pharmacies 40

Specialty Pharmacies FDA Approval Pharmaceutical Companies Pharmacy 40